Sign In
Buy BIO
$301.90
-2.46 (-0.81%)
At Close: Jul 20, 2026
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
09:00am, Friday, 02'nd May 2025
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
10:35pm, Thursday, 01'st May 2025
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Opera
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
06:40pm, Thursday, 01'st May 2025
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.
Bio-Rad Reports First-Quarter 2025 Financial Results
04:15pm, Thursday, 01'st May 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of Non-Compliance
04:30pm, Thursday, 24'th Apr 2025
HOLMDEL, N.J. , April 24, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuri
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 24'th Apr 2025
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
10:00am, Thursday, 03'rd Apr 2025
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin & Lower Operating Costs, Offsetting 11% Revenue Decrease From Business Transition.
BIO-key (BKYI) Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time.
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
04:05pm, Monday, 24'th Mar 2025
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its four
Identity, Access Management & Biometric Solutions Provider BIO-key International Hosts Q4 Investor Call Thursday, March 27th at 10am ET
08:27am, Thursday, 20'th Mar 2025
Identity, Access Management & Biometric Solutions Provider BIO-key International (Nasdaq: BKYI) Hosts Q4 Investor Call Thursday, March 27th at 10am ET.
Enveric Biosciences Participating in BIO-Europe Spring®
01:40pm, Monday, 17'th Mar 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-m
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of b
BIO-key (BKYI) Partners with California Ed Tech JPA to Make Identity & Access Management Solutions Available to 195 Member Institutions and 2.6M Students.
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
07:00am, Thursday, 13'th Mar 2025
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a p
